Some of the world’s biggest pharmaceuticals groups are facing calls to break up their diversified businesses in favour of greater focus as shareholders push for higher returns on investment.
In recent days, Johnson & Johnson has been urged to review its sprawling portfolio that ranges from baby oil to cancer drugs, and there were questions for Novartis over the future of its struggling eyecare business.
